Protara Therapeutics, Inc.
Business
Protara Therapeutics is a clinical-stage biopharmaceutical company developing transformative therapies for cancer and rare diseases. The company is advancing TARA-002, an investigational cell therapy based on OK-432 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a phospholipid substrate replacement therapy for patients on parenteral support. Protara operates in oncology and rare disease segments with development programs in the U.S. and plans for future geographic expansion following regulatory approvals.
Summary from 10-K filed 2026-03-10
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 43 | 32 | 25 | 17 | 21 | |
| General and administrative | 22 | 17 | 19 | 21 | 26 | |
| Total operating expenses | 65 | 49 | 44 | 67 | 47 | |
| Income (Loss) from operations | −65 | −49 | −44 | −67 | −47 | |
| Interest and investment income (expense) | 6 | 4 | 3 | 1 | 237,000 | |
| Other income (expense) | 730,000 | 387,000 | — | — | — | |
| Other income (expense), net | 7 | 5 | 3 | 1 | 237,000 | |
| Net income (loss) | −57 | −45 | −40 | −66 | −47 | |
| Net unrealized gain (loss) on marketable debt securities | 88,000 | 33,000 | — | — | — | |
| Other comprehensive income (loss) | 88,000 | 33,000 | 657,000 | −477,000 | −211,000 | |
| Comprehensive income (loss) | −57 | −45 | −40 | −66 | −47 | |
| Net income (loss) per share attributable to common stockholders, basic (in Dollars per share) | −1.34 | −2.17 | −3.57 | −5.86 | −4.21 | |
| Net income (loss) per share attributable to common stockholders, diluted (in Dollars per share) | −1.34 | −2.17 | −3.57 | −5.86 | −4.21 | |
| Weighted-average shares outstanding, basic (in Shares) | 43 | 21 | 11 | 11 | — | |
| Weighted-average shares outstanding, diluted (in Shares) | 43 | 21 | 11 | 11 | 11 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 50 | 163 | 40 | 24 | 36 | |
| Marketable debt securities | 106 | 7 | 26 | 60 | 56 | |
| Prepaid expenses and other current assets | 4 | 2 | 3 | 2 | 2 | |
| Total current assets | 160 | 172 | 69 | 86 | 93 | |
| Restricted cash, non-current | 745,000 | 745,000 | 745,000 | 745,000 | 745,000 | |
| Marketable debt securities, non-current | 42 | — | — | 18 | 39 | |
| Property and equipment, net | 759,000 | 1 | 1 | 2 | 2 | |
| Operating lease right-of-use asset | 3 | 4 | 5 | 6 | 7 | |
| Other assets | 3 | 3 | 3 | 644,000 | — | |
| Total assets | 209 | 181 | 79 | 113 | 173 | |
| Accounts payable | 3 | 4 | 2 | 2 | 954,000 | |
| Accrued expenses and other current liabilities | 6 | 5 | 3 | 3 | 2 | |
| Operating lease liability | 1 | 1 | 983,000 | 917,000 | 855,000 | |
| Total current liabilities | 11 | 11 | 6 | 6 | 4 | |
| Operating lease liability, non-current | 2 | 3 | 4 | 5 | 6 | |
| Total liabilities | 13 | 14 | 11 | 11 | 11 | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series 1 convertible preferred stock, 8,028 shares authorized at December 31, 2025 and 2024, 5,615 and 7,991 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | — | — | — | — | — | |
| Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 53,587,260 and 35,044,772 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 54,000 | 35,000 | 11,000 | 11,000 | 11,000 | |
| Additional paid-in capital | 499 | 412 | 269 | 263 | 256 | |
| Accumulated deficit | −302 | −245 | −200 | −160 | −94 | |
| Accumulated other comprehensive income (loss) | 90,000 | 2,000 | −31,000 | −688,000 | −211,000 | |
| Total stockholders equity | 196 | 167 | 68 | 102 | 162 | |
| Total liabilities and stockholders equity | 209 | 181 | 79 | 113 | 173 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 4 | 4 | 6 | 7 | 10 | |
| Operating lease right-of-use asset | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 362,000 | 332,000 | 341,000 | 248,000 | 117,000 | |
| Realized loss (gain) on redemption of marketable debt securities | −9,000 | — | — | — | — | |
| Amortization of premium (Accretion of discount) on marketable debt securities | −1 | −685,000 | −444,000 | 1 | 2 | |
| Prepaid expenses and other current assets | −2 | 1 | −1 | 265,000 | −418,000 | |
| Other assets | 322,000 | −328,000 | −2 | 222,000 | 295,000 | |
| Accounts payable | −873,000 | 1 | 848,000 | 631,000 | 40,000 | |
| Accrued expenses and other current liabilities | 821,000 | 3 | −505,000 | 748,000 | 576,000 | |
| Operating lease liabilities | −1 | −984,000 | −917,000 | — | — | |
| Net cash provided by (used in) operating activities | −56 | −36 | −38 | −26 | −35 | |
| Purchase of marketable debt securities | −205 | −29 | −12 | −44 | — | |
| Proceeds from maturity and redemption of marketable debt securities | 65 | 49 | 65 | 59 | — | |
| Purchase of property and equipment | −94,000 | −63,000 | −45,000 | −120,000 | −596,000 | |
| Net cash provided by (used in) investing activities | −139 | 19 | 53 | 15 | −98 | |
| Proceeds from December 2024 Public Offering, net of offering costs of $6,051 | — | 94 | — | — | — | |
| Proceeds from private placement, net of offering costs of $3,034 | — | 42 | — | — | — | |
| Proceeds from exercise of Underwriters Option in December 2024 Public Offering, net of offering costs of $214 | 3 | — | — | — | — | |
| Offering costs paid in connection with the December 2024 Public Offering | −614,000 | — | — | — | — | |
| Proceeds from December 2025 Public Offering, net of offering costs of $5,286 | 81 | — | — | — | — | |
| Proceeds from exercise of stock options | 21,000 | 135,000 | — | — | — | |
| Taxes paid related to net share settlement of restricted stock units | −185,000 | −83,000 | −91,000 | — | — | |
| Net cash provided by (used in) financing activities | 83 | 140 | −91,000 | −90,000 | −228,000 | |
| Net increase (decrease) in cash and cash equivalents and restricted cash | −113 | 123 | 15 | −12 | −133 | |
| Interest | — | — | — | — | — | |
| Income taxes | — | — | — | — | — | |
| Proceeds from public offering offering costs incurred but not paid | 526,000 | 614,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Protara Therapeutics, Inc.'s CIK number?
Protara Therapeutics, Inc.'s SEC CIK number is 0001359931 (1359931). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Protara Therapeutics, Inc.'s SEC filings?
All of Protara Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Protara Therapeutics, Inc. last report earnings?
Protara Therapeutics, Inc. (TARA) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-055462). This is Protara Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Protara Therapeutics, Inc.'s most recent earnings 8-K?
Protara Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001213900-26-055462. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Protara Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →